

OPAT WORKSHOP 2025

LONDON

5 September
Cavendish Square, London



OPAT
Outpatient Parenteral
Antimicrobial Therapy



BSAC

Welcome to the OPAT Regional Workshops 2025

Workshops will take place between June – September 2025.

BSAC are delighted to welcome you to this one-day regional workshop on Outpatient Parenteral Antimicrobial Therapy (OPAT).

The OPAT initiative is a multi-stakeholder project that supports, guides and encourages the establishment of standardised OPAT services throughout and where ever the need may arise. This workshop is bringing together OPAT experts and we hope that you take the opportunity to share expertise, discuss success stories and learn about upcoming challenges in the OPAT setting.

BSAC is very grateful to the range of companies present for their support of the workshops which enable us to keep registration fees to a minimum. We would encourage you, if you feel able, to please support our sponsors by visiting their stands during the networking breaks.

This workshop is CPD accredited and a link to download your certificate will be sent via email after the conference closes.

Follow us on:



0855

Registration

0925

Welcome and introduction

Mark Gilchrist, Consultant Pharmacist
Infectious Diseases, Imperial College
Healthcare NHS Trust & Carolyn Hemsley,
Infectious Diseases and Microbiology
Consultant, Guy's & St Thomas' NHS
Foundation Trust

SESSION 1:

0930

**BSAC OPAT Initiative overview –
Where are we now?**

Mark Gilchrist, Consultant Pharmacist
Infectious Diseases, Imperial College
Healthcare NHS Trust

0945

**BSAC OPAT Good Practice
Recommendations – a first look
[virtual presentation]**

Ann Noble, NHS Lanarkshire

1005

**Governance structure in OPAT –
Reflections from Homerton**

Jenniferth Aviles Moreta, Clinical Nurse
Specialist, OPAT and Vascular Access
Service, Homerton Healthcare NHS
Foundation Trust, London

1020

**OPAT delivery through Haemodialysis
– still OPAT?**

Carolyn Hemsley, Infectious Diseases and
Microbiology Consultant, Guy's & St Thomas'
NHS Foundation Trust

1035

Q&A

1050

Break**SESSION 2 : Spotlight on....****Long acting agents**

1120

**Dalbavancin to facilitate early
discharge in the treatment of
complex musculoskeletal infections:
a multi-centre real life application**

Tariq Azamgarhi, Royal National Orthopaedic
Hospitals NHS Trust

1135

**Early use of Rezafungin: a case series
St George's**

Tihana Bicanic, City St George's, University of
London & St George's Hospital

1150

Q&A**Clinical cases/
conundrums**

1200

**Mission Possible: Reframing barriers
to OPAT self-administration in
vulnerable patients**

Gianni Acuram, King's College Hospital

1215

Teething

Adam Gray, Lewisham & Greenwich NHS Trust

1230

Candida glabrata in the Kidney: A COPAT Conundrum

Turnera Corrah, London North West University
Healthcare NHS Trust

1245

Q&A

Innovations

1300

Initial results of an OPAT PPS pilot within London

Shay Khan, Infection and OPAT Pharmacist
Practitioner, Whittington Health NHS Trust

1315

Q&A

1330

Lunch

SESSION 3 : Focus on Endocarditis

1430

Endocarditis & OPAT – An overview

Cristina Suarez, Barts Health NHS Trust

1500

Discussion of local issues

1615

Summary and close

Mark Gilchrist, Consultant Pharmacist
Infectious Diseases, Imperial College
Healthcare NHS Trust & Carolyn Hemsley,
Infectious Diseases and Microbiology
Consultant, Guy's & St Thomas' NHS
Foundation Trust



Jenniferth Aviles Moreta

*The Homerton University Hospital
NHS Foundation Trust*

Jenniferth has specialised in Outpatient Parenteral Antimicrobial Therapy (OPAT) and Vascular Access since 2015.

Currently the Lead Clinical Nurse Specialist for the OPAT and Vascular Access service at Homerton Hospital, she is dedicated to making care as seamless as possible for patients; ensuring they can continue their treatment safely in the comfort of their own home and return to the things that matter most in their lives.

Passionate about early discharge and patient-centred care, Jenniferth works closely with a multidisciplinary team to combine clinical excellence with compassion, helping each patient feel supported every step of the way.



Tariq Azamgarhi

*Royal National Orthopaedic Hospitals
NHS Trust*

I am an antimicrobial pharmacist at the Royal National Orthopaedic Hospitals NHS Trust. I specialise in treating bone infections within the

MDT. My interests include OPAT and antimicrobial stewardship. I also have a research interest and am currently undertaking a PhD project on surgical prophylaxis in primary bone sarcomas.



Tihana Bicanic

*City St George's, University of London
& St George's Hospital*

Professor Bicanic is a Fellow of the European Confederation of Medical Mycology FECMM – ECMM in recognition of scientific excellence and outstanding expertise in Medical Mycology. She is regularly invited to speak at major International Infectious Diseases and Mycology conferences (ESCMID, TIMM, ISHAM). She is a also member of the antifungal subcommittee of the UK Health Security Agency ESPAUR (English antimicrobial utilisation and resistance oversight) group.

Previously on the Scientific Advisory Committee of British Infection Association Scientific Advisory committee (2017–23), she is a current panel member of the Pathogen Biology and Disease Transmission Discovery Advisory Group – Grant Funding | Wellcome

Since 2020, she has been the Director of the Infection Clinical Academic Group (sgul.ac.uk) which fosters clinical research excellence and promotes links between researchers at St George's NHS Trust and the University.



Mark Gilchrist

Imperial College Healthcare NHS Trust

Mark is a Consultant Pharmacist Infectious Diseases & Head of Antimicrobial Stewardship Programme at Imperial College Healthcare NHS Trust.

He is a council member of British Society of Antimicrobial Chemotherapy and co-chairs its UK OPAT Initiative. He is Professor of Practice (Infectious Diseases) at Imperial College London, together with being a spokesman on antimicrobials and fellow of the Royal Pharmaceutical Society.

Mark has particular interests in antimicrobial stewardship around improving systems and processes that affect local, national and international AMR. His clinical interests include OPAT, tuberculosis and critical care.

Postgraduate education includes an MSc and non-medical independent prescribing status and he was recently awarded the NHS Leadership Academy Nye Bevan Award in executive healthcare leadership.

He is a past chair of the UK Clinical Pharmacy Association – Pharmacy Infection Network (UKCPA PIN) and was awarded RPS Faculty Fellowship (Infection) in 2013.

He has delivered many lectures and workshops on AMS both at national and international level and has published around his areas of interest.



Adam Gray

Lewisham & Greenwich NHS Trust

Adam Gray is a consultant of Infectious Diseases and General Internal Medicine and OPAT lead at University Hospital Lewisham in south-east London. He graduated from Cardiff University and recently completed ID training in London having also spent time working abroad.



Carolyn Hemsley

Infectious Diseases and Microbiology Consultant, Guy's & St Thomas' NHS Foundation Trust

Carolyn Hemsley is a Consultant in Infectious Diseases and Microbiology at Guy's and St Thomas' NHS Foundation Trust (GSTT) and Lead for Guys Hospital. She is the Clinical Lead for the Adult OPAT service at GSTT and has supported BSAC OPAT initiative since it's inception. She has a particular interest in bone and joint infection and infection in patients with Cancer supporting Guys Cancer Centre.



Shay Khan

*Infection and OPAT Pharmacist Practitioner,
Whittington Health NHS Trust*

Shay Khan, Infection and OPAT Pharmacist | Advanced Practitioner, Whittington Health NHS Trust

Shay graduated with an MPharm from UCL School of Pharmacy in 2016. He went on to complete his post-graduate MSc in Clinical Pharmacy and Pharmacology at University of Bath in 2022 and is currently undertaking an MSc in Advanced Clinical Practice at London South Bank University. Prior to joining Whittington, he trained as a non-medical prescriber at Royal Free Hospital. Since joining the Whittington, Shay has helped set up and expand the OPAT service, including the use of nurse-filled elastomerics and setting up novel pathways across virtual wards. He has led on the development of Whittington Health's first automated Power BI dashboard, designed to monitor OPAT service performance, antimicrobial stewardship, and key safety indicators. This innovative project has earned the OPAT team nominations for the 2025 UKHSA Antibiotic Guardian Awards and the 2025 HSJ Digital Awards. His research includes safe and effective use of elastomerics in the community and the impact of advanced practitioner roles in infection/OPAT settings. Shay's interests include advancing clinical pharmacist roles in infection, AMR and Health Analytics.



Cristina Suarez

*Lead consultant for OPAT,
St Bartholomew's Hospital*

I am an infectious diseases and microbiology consultant working at Barts Health NHS Trust. This includes working several months per year at St Bartholomew's Hospital, centre for specialised cardiology and cardiac surgery, as well as haematology/oncology, complex intensive care and ECMO patients and complex respiratory conditions. Our relatively young OPAT service at St Bartholomew's cares mainly for patients with endovascular infections, including endocarditis. We aim to have an integrated, flexible, patient-centered service. These are complex patients at higher risk of relapse and failure, and specific OPAT arrangements need to be considered if you are including them into your cohort. We will walk you through our experience so far, the pros and the cons. Is your service ready to accept these patients? Are you ready? Are your patients ready?

Baxter

Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

For more information about Baxter visit www.baxterhealthcare.co.uk, www.baxterhealthcare.ie or follow us on LinkedIn.

Baxter is a registered trademark of Baxter International Inc.

B | BRAUN

SHARING EXPERTISE

B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. With over 64,000 employees in 64 countries, B. Braun develops high quality product systems and services for users around the world.

Every service provided by B. Braun incorporates its entire expertise and the company's deep understanding of users' needs. In developing its products, product systems and services, B. Braun acts as a partner. A companion who promotes developments through constructive dialogue and the motivation to

improve things. With its constantly growing portfolio of effective medical care solutions, B. Braun makes a substantial contribution towards protecting and improving people's health.

For more information about our products and offerings please visit: www.bbraun.co.uk



Eumedica is an independent and international pharmaceutical company that aims to ensure medical care continuity. We offer an extensive range of products and services, covering healthcare stakeholders' needs, in two domains of expertise:

- A comprehensive logistics service for worldwide clinical trial supplies and authorised human medicines
- Marketing and distributing pharmaceutical products



A. Menarini Farmaceutica Internazionale SRL in the UK, is dedicated to launching products that respond to the genuine medical needs of patients and physicians, the company now markets a portfolio of products in the areas of microbiology and infectious disease.

For more information on our anti-infective portfolio please contact antibiotics@menariniuk.com

Adverse events should be reported. Reporting forms and information

can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL. Phone no. 0800 085 8678 or email: menarini@medinformation.co.uk



A member of the Mundipharma network of associated companies

Napp Pharmaceuticals Limited is part of Mundipharma, a global healthcare company dedicated to bringing innovative treatments to patients in infectious disease and other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit

www.napp.co.uk



At Pfizer, we apply science and our global resources to bring therapies to people that extend and improve their lives. Today, Pfizer UK offers a diverse portfolio to patients including over 20 antibacterial and antifungal medicines. With infectious disease continuing to be a threat to global health, Pfizer is supporting the appropriate use of antibacterial/antifungal agents to protect patient health.

PP-CRB-GBR-2346 | February 2024



TILLOTTS PHARMA

Tillotts Pharma AG has a strong presence in Europe with affiliates and distributors in all major European markets. The UK business is the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, and part of the Japanese Zeria Group.

Tillotts Pharma UK Ltd was established in March 2010. Jeremy Thorpe (Managing Director) joined in July 2012, with a clear focus on optimising the portfolio of gastrointestinal (GI) health products. Tillotts Pharma UK is now a market leader.

GI health is our passion at Tillotts. With over 30 years' expertise in developing and manufacturing treatments for inflammatory bowel disease (IBD), we understand the disease, the market and the challenges GI healthcare professionals and patients face. Tillotts Pharma UK strive to be the preferred partner in GI health and are committed to supporting the NHS to improve outcomes for patients. Tillotts are motivated by the aim to consistently deliver quality and value to the NHS and are dedicated to improving the lives of people with GI disease and supporting those who care for them.



Founded in 1971, the British Society for Antimicrobial Chemotherapy (BSAC) is committed to addressing the growing threat of drug resistant infections – one of leading global causes of death.

As one of the world's largest networks of infection specialists, BSAC works with a wide range of stakeholders, including researchers, scientists, health care providers, policymakers, and industry leaders to support their work and help them reach a global audience.

BSAC's renowned publications are among the foremost international journals in antimicrobial research, whilst its commitment to scientific excellence is reflected in a varied programme of events, training, accreditation and free educational resources.

www.bsac.org.uk